Springer Jason M, Byram Kevin
Department of Medicine, Division of Rheumatology and Immunology, Vanderbilt University Medical Center, Nashville, Tennessee, USA.
Postgrad Med. 2023 Jan;135(sup1):61-68. doi: 10.1080/00325481.2022.2088940. Epub 2022 Jun 22.
Polyarteritis nodosa (PAN) is a primary form of vasculitis characterized by inflammation of primarily medium-sized arteries. Several key events have shaped the current spectrum of the disease including the separation of a subgroup with microscopic polyangiitis, the discovery of the association of hepatitis B, and the discovery of adenosine deaminase 2 deficiency (DADA2). With the discovery of secondary causes of PAN and changing nomenclature, the incidence of PAN has declined over time. Common manifestations include constitutional symptoms, skin involvement, peripheral neuropathy, gastrointestinal disease, and renal involvement. DADA2 is a genetic cause of medium vessel vasculitis that is important to distinguish from primary PAN as treatment with TNF inhibitors can prevent morbidity and mortality in those with a vasculitis phenotype. Treatment of systemic primary PAN involves the use of systemic immunosuppressive therapy largely guided by the severity of disease. With current treatment regimens, the prognosis has changed from a once uniformly fatal disease to a 5-year survival rate above 80%.
结节性多动脉炎(PAN)是一种原发性血管炎,主要特征为中等大小动脉的炎症。几个关键事件塑造了该病目前的范畴,包括与显微镜下多血管炎的亚组分离、乙型肝炎关联的发现以及腺苷脱氨酶2缺乏症(DADA2)的发现。随着PAN继发性病因的发现和命名的变化,PAN的发病率随时间下降。常见表现包括全身症状、皮肤受累、周围神经病变、胃肠道疾病和肾脏受累。DADA2是中血管血管炎的一个遗传病因,由于使用肿瘤坏死因子抑制剂治疗可预防有血管炎表型患者的发病和死亡,因此有必要将其与原发性PAN区分开来。系统性原发性PAN的治疗主要依据疾病严重程度使用全身免疫抑制疗法。采用当前的治疗方案,预后已从曾经一致认为的致命疾病转变为5年生存率超过80%。